These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 32974185)

  • 1. Corrigendum: The Emerging Role of the c-MET-HGF Axis in Non-small Cell Lung Cancer Tumor Immunology and Immunotherapy.
    Titmarsh HF; O'Connor R; Dhaliwal K; Akram AR
    Front Oncol; 2020; 10():1516. PubMed ID: 32974185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Emerging Role of the c-MET-HGF Axis in Non-small Cell Lung Cancer Tumor Immunology and Immunotherapy.
    Titmarsh HF; O'Connor R; Dhaliwal K; Akram AR
    Front Oncol; 2020; 10():54. PubMed ID: 32117721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Corrigendum: Progress and perspectives of perioperative immunotherapy in non-small cell lung cancer.
    Peng Y; Li Z; Fu Y; Pan Y; Zeng Y; Liu J; Xiao C; Zhang Y; Su Y; Li G; Wu F
    Front Oncol; 2023; 13():1163376. PubMed ID: 37064096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Corrigendum: Lipid metabolism in tumor immunology and immunotherapy.
    Duong LK; Corbali HI; Riad TS; Ganjoo S; Nanez S; Voss T; Barsoumian HB; Welsh J; Cortez MA
    Front Oncol; 2023; 13():1358498. PubMed ID: 38260855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of HGF/MET axis in resistance of lung cancer to contemporary management.
    Raghav KP; Gonzalez-Angulo AM; Blumenschein GR
    Transl Lung Cancer Res; 2012 Sep; 1(3):179-93. PubMed ID: 25806180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Constitutive activation of met kinase in non-small-cell lung carcinomas correlates with anchorage-independent cell survival.
    Qiao H; Hung W; Tremblay E; Wojcik J; Gui J; Ho J; Klassen J; Campling B; Elliott B
    J Cell Biochem; 2002; 86(4):665-77. PubMed ID: 12210733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Status of Agents Targeting the HGF/c-Met Axis in Lung Cancer.
    Miranda O; Farooqui M; Siegfried JM
    Cancers (Basel); 2018 Aug; 10(9):. PubMed ID: 30134579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Corrigendum: Afatinib for Advanced Non-small Cell Lung Cancer in a Case With an Uncommon Epidermal Growth Factor Receptor Mutation (G719A) Identified in the Cerebrospinal Fluid.
    Ma C; Huang C; Tang D; Ye X; Li Z; Liu R; Mu N; Li J; Jiang R; Zhang J
    Front Oncol; 2019; 9():938. PubMed ID: 31641649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Signaling pathways involved in cyclooxygenase-2 induction by hepatocyte growth factor in non small-cell lung cancer.
    Siegfried JM; Gubish CT; Rothstein ME; Queiroz de Oliveira PE; Stabile LP
    Mol Pharmacol; 2007 Sep; 72(3):769-79. PubMed ID: 17550984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the tumor-promoting microenvironment in MET-amplified NSCLC cells with a novel inhibitor of pro-HGF activation.
    Owusu BY; Thomas S; Venukadasula P; Han Z; Janetka JW; Galemmo RA; Klampfer L
    Oncotarget; 2017 Sep; 8(38):63014-63025. PubMed ID: 28968967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Corrigendum: The
    Bian X; Wang X; Zhang Q; Ma L; Cao G; Xu A; Han J; Huang J; Lin W
    Front Oncol; 2023; 13():1192526. PubMed ID: 37124537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatocyte growth factor produced in lung fibroblasts enhances non-small cell lung cancer cell survival and tumor progression.
    Kanaji N; Yokohira M; Nakano-Narusawa Y; Watanabe N; Imaida K; Kadowaki N; Bandoh S
    Respir Res; 2017 Jun; 18(1):118. PubMed ID: 28619066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Corrigendum: Immune cell-lipoprotein imbalance as a marker for early diagnosis of non-small cell lung cancer metastasis.
    Zhang W; Wang W; Wu J; Tian J; Yan W; Yuan Y; Yao Y; Shang A; Quan W
    Front Oncol; 2022; 12():1118042. PubMed ID: 36591456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Corrigendum: Serum cytokine levels for predicting immune-related adverse events and the clinical response in lung cancer treated with immunotherapy.
    Zhao N; Yi Y; Cao W; Fu X; Mei N; Li C
    Front Oncol; 2022; 12():1069999. PubMed ID: 36582794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Corrigendum: Predicting Outcomes From Radical Radiotherapy for Non-small Cell Lung Cancer: A Systematic Review of the Existing Literature.
    Walls GM; Hanna GG; Qi F; Zhao S; Xia J; Ansari MT; Landau D
    Front Oncol; 2019; 9():112. PubMed ID: 30881918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non-Small-Cell Lung Cancer.
    Lara MS; Holland WS; Chinn D; Burich RA; Lara PN; Gandara DR; Kelly K; Mack PC
    Clin Lung Cancer; 2017 May; 18(3):281-285. PubMed ID: 28038979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Corrigendum: Advanced lung cancer inflammation index predicts survival outcomes of hepatocellular carcinoma patients receiving immunotherapy.
    Li Q; Ma F; Wang JF
    Front Oncol; 2024; 14():1431058. PubMed ID: 38915365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erratum: The landscape of immunotherapy resistance in NSCLC.
    Frontiers Production Office
    Front Oncol; 2023; 13():1187021. PubMed ID: 37081979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Corrigendum: Association of
    Chen H; Chong W; Wu Q; Yao Y; Mao M; Wang X
    Front Immunol; 2019; 10():1523. PubMed ID: 31312207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Research Progress of HGF/c-MET Inhibitor in the Treatment of Non-small Cell Lung Cancer].
    Jiang T; Zhou C
    Zhongguo Fei Ai Za Zhi; 2015 Apr; 18(4):240-4. PubMed ID: 25936889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.